We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders. Learn more
CLINUVEL has taken a keen interest and active role in research and development in photomedicine, investigating the interaction of light and human biology and pioneering the concept of medicinal photoprotection – protecting skin from light. Learn more
As pioneers and leaders in understanding the interaction of light and human biology, CLINUVEL’s products have been developed after years of extensive scientific research and understanding of rare disorders. Learn more
As pioneers in medicinal photoprotection, we are continually striving to expand our deep reservoir of knowledge and expertise within the broader field of photocare. Learn more
CLINUVEL takes pride in connecting with as many people as possible online. Join us on any of our social channels to keep up to date for latest company developments. Learn more
CLINUVEL’s Investor Area contains a range of information for investors including latest announcements, share price information and answers to frequently asked questions.Learn more
CLINUVEL is listed on the Australian Securities Exchange under the ticker code CUV.
CLINUVEL’s Annual Report for the year ended 30 June 2017.
Download 2017 Annual Report
CLINUVEL PHARMACEUTICALS sites use cookies to improve and personalise your experience. The sites may also include cookies from third parties. By using this site, you consent to the use of cookies. Learn More
